$10.41

(%)
Live
Previous Close

$10.41

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$381.9 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

New York Stock Exchange

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical imp...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

Analysts' ratings for Nevro (NYSE:NVRO) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 2 0 0 3M Ago 0 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.0, along with a high estimate of $20.00 and a low estimate of $16.00. Experiencing a 14.29% decline, the current average is now lower than the previous average price target of $21.00. Exploring Analyst Ratings: An In-Depth Overview In examining recent analyst actions, we gain insights into how financial experts perceive Nevro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joanne Wuensch Citigroup Lowers Neutral $16.00 $18.00 Lawrence Biegelsen Wells Fargo Lowers Equal-Weight $17.00 $20.00 Mike Polark Baird Lowers Neutral $19.00 $23.00 Shagun Singh RBC Capital Lowers Sector Perform $20.00 $23.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Nevro. This offers insight into analysts' perspectives on the current state of the company. Rating: Providing a comprehensive analysis, analysts offer ...Full story available on Benzinga.com

Related tickers: NVRO.

Read Full Article

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

Related tickers: ABT, BSX, MDT, NVRO.

Read Full Article
Trending Tickers
DATS

XNAS

$1.25
(%)
LASE

XNAS

$1.95
(%)
BFRG

XNAS

$3.14
(%)
BMR

XNAS

$5.54
(%)
MLGO

XNAS

$0.00
(%)